Results 231 to 240 of about 255,779 (244)

Expansion of bone marrow adipocytes in obese mice leads to PD-L1-driven bone marrow immunosuppression and osteoclastogenesis. [PDF]

Bone Res
Costa SN, Chlebek C, Gray L, Caradonna P, Ryzhov S, Rosen CJ.   +5 more
europepmc   +1 more source

Tumor‐Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities

Advanced Science, EarlyView.
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley   +1 more source

IL-1β Upregulates PD-L1 in Small Extracellular Vesicle of Endothelial Origin. [PDF]

FASEB J
Gagliardi MC, Felicetti F, Bertuccini L, Ortona E, Bolego C, Fecchi K.   +5 more
europepmc   +1 more source

Enantioselective Reductive Alkenylation of α‐CF2H (‐CF3) Amino Halides: Rapid Access to Chiral α‐CF2H (‐CF3) Allylamines

Advanced Science, EarlyView.
Difluoromethyl (CF2H) group, the bioisostere of hydroxyl thiol methyl or amide is privileged in medicinal chemistry due to hydrogen‐binding ability and lipophilic, metabolically stable, and chemical inert nature. However, enatioseleceive CF2H introduction remains challenging.
Peng Liu, Kuiliang Li, Yan He, Chen‐Hui Jiang, Ruo‐Xing Jin, Duo‐Duo Hu, Wei‐Cheng Zhao, Xuan Nie, Shang‐Zheng Sun, Xi‐Sheng Wang   +9 more
wiley   +1 more source

HMGN2 induces pyroptosis in tumour cells by modulating the STT3B/PD‑L1/caspase‑1/GSDMD axis. [PDF]

Mol Med Rep
Han W, Chen H, Cui B, Chen J, Zhang P, Feng Y.   +5 more
europepmc   +1 more source

Nanozymes for Liver Disease Therapy: Advances in Catalytic Activity, Targeting Strategies, and Clinical Translation

Advanced Science, EarlyView.
Nanozymes, as enzyme‐mimicking nanomaterials, exhibit unique catalytic properties for the treatment of liver diseases. By regulating redox homeostasis, modulating immune responses, and enabling targeted delivery, nanozymes overcome the limitations of natural enzymes.
Xiandi Meng, Ge Zhu, Siyu Sun, Wenbo Yao, Yuning Zhang, Yong‐Guang Yang, Tianmeng Sun   +6 more
wiley   +1 more source

Advances in the application of PD-1/PD-L1 immunotherapy for prostate cancer: a review. [PDF]

Front Immunol
Hu G, Li Z, Chen Y, Liao H, Zhou S.
europepmc   +1 more source

PD-1/PD-L1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis. [PDF]

Medicine (Baltimore)
Bai W, Xu S, Miao L, Zhao J, Zhao L, Gao Z, Liu T.   +6 more
europepmc   +1 more source

Triple targeting of STING, TGF-β, and PD-L1 boosts CXCL16-CXCR6 signaling for potent antitumor response. [PDF]

Nat Commun
Yi M, Li T, Gu Y, Niu M, Xue D, Hu S, Wu Y, Zhao B, Zhang D, Ma Y, Zhang M, Zhang J, Yan Y, Zhou P, Zhang X, Zhou Z, Chu Q, Wu K, Dai Z.   +18 more
europepmc   +1 more source

Intracellular Localization of PD-L1 in Rab10-positive Open Tubular Endosome System of Cancer Cells. [PDF]

Acta Histochem Cytochem
Yamada R, Sakamoto R, Kawai K, Egami Y, Araki N.   +4 more
europepmc   +1 more source